Tenax Therapeutics

Morrisville, United States Founded: 1967 • Age: 59 yrs
Developer of therapeutics to address cardiovascular and pulmonary diseases
Annual revenue - Latest available
Total funding - 11 rounds
Employees 6 Tracked headcount
Investors 2 Known backers
Products 2 Services tracked
Competitors 11 Brand Intelligence

About Tenax Therapeutics

Tenax Therapeutics is a company based in Morrisville (United States) founded in 1967. The company has 6 employees as of December 31, 2024. Tenax Therapeutics offers products and services including TNX-201 and TNX-103. Tenax Therapeutics operates in a competitive market with competitors including Actelion, AskBio, Juvenescence, Inotrem and Aerovate Therapeutics, among others.

  • Headquarter Morrisville, United States
  • Employees 6 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Tenax Therapeutics, Inc.
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    -$17.6 M (USD)
    -128.28
    as on Dec 31, 2024
  • EBITDA
    -$19.49 M (USD)
    -136.97
    as on Dec 31, 2024
  • Latest Funding Round
    $25 M (USD), Post-IPO

    Mar 05, 2025

  • Investors
  • Employee Count
    6

    as on Dec 31, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Tenax Therapeutics

Tenax Therapeutics is a publicly listed company on the NASDAQ with ticker symbol TENX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: TENX · Sector: Health technology · USA

Products & Services of Tenax Therapeutics

Tenax Therapeutics offers a comprehensive portfolio of products and services, including TNX-201 and TNX-103.

Product name locked
Category locked
Primary

Oral enteric coated imatinib for pulmonary hypertension treatment.

Product name locked
Category locked
Locked

Oral levosimendan for cardiopulmonary condition therapies.

People of Tenax Therapeutics

Headcount 10-50
Employee Profiles 6
Board Members and Advisors 12
Employee Profiles
People
Chris Giordano
President & CEO
People
Stuart Rich
Chief Medical Officer
People
Douglas Hay
SVP of Regulatory Affairs
People
Doug Randall
EVP of Commercial and Business Operations

Unlock access to complete

Board Members and Advisors
people
Declan Doogan
Director
people
Robert Frantz
Scientific Advisor
people
Gerald Proehl
Chairman, Board of Directors
people
Sanjiv Shah
Scientific Advisor

Unlock access to complete

Funding Insights of Tenax Therapeutics

Investors in Tenax Therapeutics

Tenax Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include RTW Investments and Military Health.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Life Sciences focused VC firm investing in the US
Locked Locked Locked
Administers health care and support for military personnel and operations.
Locked Locked Locked
Premium access

Investor details for Tenax Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Tenax Therapeutics

Investments
Premium access

Investment portfolio details for Tenax Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Tenax Therapeutics

Premium access

Detailed financials for Tenax Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Tenax Therapeutics Comparisons

Tenax Therapeutics Primary company
Description
Developer of therapeutics to address cardiovascular and pulm...
Location
Morrisville, United States
Founded Year
1967
Annual Revenue
Not available
Net Profit
-$17.6 M (USD)
EBITDA
-$19.49 M (USD)
Employees
6
As of 2024
Premium access

Peer comparison for Tenax Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Tenax Therapeutics

Tenax Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, AskBio, Juvenescence, Inotrem and Aerovate Therapeutics, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
Locked Locked Locked
Gene and protein therapies are developed for treating various diseases.
Locked Locked Locked
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health
Locked Locked Locked
Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction
Locked Locked Locked
Therapeutic solutions for pulmonary arterial hypertension are developed.
Locked Locked Locked
Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response
Premium access

Detailed competitors of Tenax Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Tenax Therapeutics

Premium access

Complete news archive for Tenax Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Tenax Therapeutics

Tenax Therapeutics was founded in 1967 and raised its 1st funding round 42 years after it was founded.

Tenax Therapeutics is headquartered in Morrisville, United States.

As of Dec 31, 2024, the latest employee count at Tenax Therapeutics is 6.

Developer of therapeutics to address cardiovascular and pulmonary diseases. The companys pipeline include levosimendan is calcium sensitizer that is approved ex-US for acute decompensated heart failure in cardiac surgery patients and Oxycyte is a PFC-based oil in water emulsion that is given intravenously to patients in order to facilitate oxygen transportation from the lungs.

Tenax Therapeutics's top competitors include Juvenescence, AskBio and Mission Therapeutics.

Tenax Therapeutics offers TNX-201 and TNX-103.

Yes, Tenax Therapeutics is publicly traded on NASDAQ under the ticker symbol TENX.

Tenax Therapeutics has 2 investors. Key investors include RTW Investments, and Military Health.

The ticker symbol of Tenax Therapeutics is TENX on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available